Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Anticholinergics on Cognitive Function in the Elderly: a Randomized Controlled Trial
Brief Summary: Anticholinergic medication is used to treat overactive bladder (OAB). A known side effect of this medication is cognitive dysfunction. OAB is more prevalent in the elderly population - a group that also has a higher baseline risk of cognitive dysfunction. Our objective is to evaluate the effect of an anticholinergic medication on cognitive function in elderly women.


Options:
A: Arm Label: BOTOX®; Type: EXPERIMENTAL; Interventions: Biological: BOTOX®, Drug: solifenacin placebo | Arm Label: solifenacin; Type: ACTIVE_COMPARATOR; Interventions: Biological: BOTOX®, Drug: solifenacin, Drug: Botox placebo (normal saline) | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: BOTOX®, Drug: Botox placebo (normal saline), Drug: solifenacin placebo | Intervention Type: BIOLOGICAL; Name: BOTOX®; Assigned to Arm(s): BOTOX®, placebo, solifenacin | Intervention Type: DRUG; Name: solifenacin; Assigned to Arm(s): solifenacin | Intervention Type: DRUG; Name: Botox placebo (normal saline); Assigned to Arm(s): placebo, solifenacin | Intervention Type: DRUG; Name: solifenacin placebo; Assigned to Arm(s): BOTOX®, placebo
B: Arm Label: TROSPIUM CHLORIDE; Type: ACTIVE_COMPARATOR; Interventions: Drug: Trospium Chloride | Arm Label: PLACEBO; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Trospium Chloride; Assigned to Arm(s): TROSPIUM CHLORIDE | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): PLACEBO
C: Arm Label: Part 1: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo matching vibegron, Drug: Placebo matching tolterodine ER | Arm Label: Part 1: vibegron 3 mg; Type: EXPERIMENTAL; Interventions: Drug: Vibegron, Drug: Placebo matching vibegron, Drug: Placebo matching tolterodine ER | Arm Label: Part 1: vibegron 15 mg; Type: EXPERIMENTAL; Interventions: Drug: Vibegron, Drug: Placebo matching vibegron, Drug: Placebo matching tolterodine ER | Arm Label: Part 1: vibegron 50 mg; Type: EXPERIMENTAL; Interventions: Drug: Vibegron, Drug: Placebo matching vibegron, Drug: Placebo matching tolterodine ER | Arm Label: Part 1: vibegron 100 mg; Type: EXPERIMENTAL; Interventions: Drug: Vibegron, Drug: Placebo matching tolterodine ER | Arm Label: Part 1: tolterodine ER 4 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tolterodine ER, Drug: Placebo matching vibegron | Arm Label: Part 1: vibegron 50 mg + tolterodine ER 4 mg/vibegron 50 mg; Type: EXPERIMENTAL; Interventions: Drug: Vibegron, Drug: Tolterodine ER, Drug: Placebo matching tolterodine ER | Arm Label: Part 2: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo matching vibegron, Drug: Placebo matching tolterodine ER | Arm Label: Part 2: vibegron 100 mg; Type: EXPERIMENTAL; Interventions: Drug: Vibegron, Drug: Placebo matching tolterodine ER | Arm Label: Part 2: tolterodine ER 4 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tolterodine ER, Drug: Placebo matching vibegron | Arm Label: Part 2: vibegron 100 mg + tolterodine ER 4 mg; Type: EXPERIMENTAL; Interventions: Drug: Vibegron, Drug: Tolterodine ER | Arm Label: Extension Study: vibegron 50 mg; Type: EXPERIMENTAL; Interventions: Drug: Vibegron, Drug: Placebo matching vibegron, Drug: Placebo matching tolterodine ER | Arm Label: Extension Study: vibegron 100 mg; Type: EXPERIMENTAL; Interventions: Drug: Vibegron, Drug: Placebo matching tolterodine ER | Arm Label: Extension Study: tolterodine ER 4 mg; Type: EXPERIMENTAL; Interventions: Drug: Tolterodine ER, Drug: Placebo matching vibegron | Arm Label: Extension Study: vibegron 100 mg + tolterodine ER 4 mg; Type: EXPERIMENTAL; Interventions: Drug: Vibegron, Drug: Tolterodine ER | Intervention Type: DRUG; Name: Vibegron; Assigned to Arm(s): Extension Study: vibegron 100 mg, Extension Study: vibegron 100 mg + tolterodine ER 4 mg, Extension Study: vibegron 50 mg, Part 1: vibegron 100 mg, Part 1: vibegron 15 mg, Part 1: vibegron 3 mg, Part 1: vibegron 50 mg, Part 1: vibegron 50 mg + tolterodine ER 4 mg/vibegron 50 mg, Part 2: vibegron 100 mg, Part 2: vibegron 100 mg + tolterodine ER 4 mg | Intervention Type: DRUG; Name: Tolterodine ER; Assigned to Arm(s): Extension Study: tolterodine ER 4 mg, Extension Study: vibegron 100 mg + tolterodine ER 4 mg, Part 1: tolterodine ER 4 mg, Part 1: vibegron 50 mg + tolterodine ER 4 mg/vibegron 50 mg, Part 2: tolterodine ER 4 mg, Part 2: vibegron 100 mg + tolterodine ER 4 mg | Intervention Type: DRUG; Name: Placebo matching vibegron; Assigned to Arm(s): Extension Study: tolterodine ER 4 mg, Extension Study: vibegron 50 mg, Part 1: placebo, Part 1: tolterodine ER 4 mg, Part 1: vibegron 15 mg, Part 1: vibegron 3 mg, Part 1: vibegron 50 mg, Part 2: placebo, Part 2: tolterodine ER 4 mg | Intervention Type: DRUG; Name: Placebo matching tolterodine ER; Assigned to Arm(s): Extension Study: vibegron 100 mg, Extension Study: vibegron 50 mg, Part 1: placebo, Part 1: vibegron 100 mg, Part 1: vibegron 15 mg, Part 1: vibegron 3 mg, Part 1: vibegron 50 mg, Part 1: vibegron 50 mg + tolterodine ER 4 mg/vibegron 50 mg, Part 2: placebo, Part 2: vibegron 100 mg
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tolterodine ER | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Fesoterodine | Intervention Type: DRUG; Name: Tolterodine ER; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Fesoterodine; Assigned to Arm(s): 3

Answer: B